Diffusion Pharmaceuticals Inc. — Form 10-Q Summary
Reporting period: Quarter ended March 31, 2016; filed May 16, 2016. The filing identifies the registrant as Diffusion Pharmaceuticals Inc. (formerly RestorGenex Corporation), not Cervomed Inc. The quarter includes the January 8, 2016 merger with Diffusion Pharmaceuticals LLC, accounted for as a reverse acquisition; historical comparisons therefore reflect Diffusion LLC on a standalone basis.
Business context and outlook
Diffusion is a clinical-stage biotechnology company with no product-sales revenue. Its lead candidate, trans sodium crocetinate (TSC), is intended to re-oxygenate tumor tissue and improve response to standard cancer treatments. The company reported a completed Phase 1/2 study in newly diagnosed glioblastoma (GBM), and said FDA discussions had resulted in agreement on the design of a single 400-patient pivotal Phase 3 study. Management expected to enter Phase 3 for GBM within 12 months, subject to available financing. Discussions regarding a first-line pancreatic cancer program were ongoing.
The company also acquired the legacy RestorGenex candidates RES-529 and RES-440. RES-529 was in preclinical oncology development; RES-440 was being developed for acne. TSC has orphan drug designations for GBM and metastatic brain cancer.
Key financial metrics
| Metric | Quarter ended March 31, 2016 | Comparable 2015 period |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $2.35 million | $0.73 million |
| General and administrative expense | $3.86 million | $0.46 million |
| Net loss | $6.22 million | $1.24 million |
| Basic and diluted loss per share | $0.06 | $0.06 |
| Net cash used in operating activities | $4.63 million | $0.94 million |
No gross profit or operating margin was reported because the company had no revenue. The increased loss per share did not show in the reported rounded figure; weighted-average shares rose to 99.96 million from 22.09 million.
At March 31, 2016, cash and cash equivalents were $5.87 million, working capital was $4.04 million, total assets were $22.91 million, and total liabilities were $6.33 million. Convertible-note principal was $550,000, with a reported fair value of approximately $2.30 million. There was no credit facility. Cash increased by $3.87 million during the quarter, largely because the merger brought in $8.50 million of cash; operating activities consumed $4.63 million.
Material changes and unusual items
- R&D expense rose by $1.62 million, mainly due to drug-manufacturing costs and initiation of the TSC pancreatic cancer program. G&A increased by $3.40 million, principally reflecting approximately $2.0 million of merger costs and $1.0 million of public-company professional fees.
- Reported cash flow included $8.50 million received in the reverse merger. The merger also added $9.32 million of in-process R&D intangible assets and $7.11 million of goodwill; purchase-price allocation remained preliminary.
- The company issued 18.61 million shares to former RestorGenex shareholders and converted $711,495 of notes and accrued interest into 2.17 million shares. Shares outstanding at March 31 were 102.43 million.
- Merger-related pro forma information showed a $4.66 million loss for Q1 2016 versus $4.76 million in Q1 2015. The pro forma 2016 loss included $1.64 million of merger transaction costs and excluded approximately $3.0 million of RestorGenex severance costs.
Liquidity, risks and contingencies
Management said March 31 cash was expected to fund operations and research and development goals into the third quarter of 2016. The company also stated it would need substantial additional financing, had no financing commitments, and might have to delay, scale back, partner, sell, or cease operations if funding were unavailable. It expected losses and higher expenses as development advanced.
Key risks include clinical-trial results and timing, regulatory approval, manufacturing, intellectual-property protection, competition, and the ability to raise capital. The $9.32 million IPR&D assets are subject to impairment testing; an impairment could result in a charge up to their carrying value. A former CEO’s arbitration claim remained unresolved, with potential loss not estimable; a former Diffusion LLC member’s amended contract claim sought issuance of additional units for $1.07 million. Management said it considered the claims without merit, while noting the former CEO matter could materially affect financial position depending on outcome.
The company said disclosure controls were effective. It reported a pre-merger material weakness related to accounting expertise and financial reporting, and stated that the period-end close weakness had been remediated as of March 31, 2016; integration of systems and controls was ongoing.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is for Diffusion Pharmaceuticals Inc., although the request metadata names Cervomed Inc.
- Track financing needs and cash runway, including whether additional capital is secured before the stated third-quarter 2016 runway endpoint.
- Verify progress, funding, and regulatory alignment for the planned 400-patient Phase 3 GBM study and the pancreatic cancer program.
- Review final merger purchase-price allocations, valuation and impairment assumptions for IPR&D and goodwill, and the substantial gap between convertible-note principal and disclosed fair value.
- Monitor litigation developments, potential dilution from shares/options/warrants, and whether control integration and remediation efforts remain effective.